# MIRA (MIRA Pharmaceuticals, Inc.) - SEC EDGAR Financial Statements

> MIRA Pharmaceuticals, Inc. reported $7.27M in total assets and a net loss of $9.76M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/MIRA
- Markdown: https://convexityos.com/fundamentals/MIRA.md
- SEC CIK: 0001904286
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 21, 2026, 05:02 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001904286&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -- | Operating profit |
| Net Income | FY 2025 | -$9.76M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$1.35 | Split-adjusted |
| Free Cash Flow | FY 2025 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $6.97M | Total debt: -- |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Research & Development | $1.72M | $3.31M | $1.57M | $2.35M |
| Total Operating Expenses | $10.49M | $8.02M | $8.53M | $7.05M |
| Interest Expense | -- | -$166K | $3.46M | $10K |
| **Net Income** | -$10.44M | -$7.85M | -$11.98M | -$7.06M |
| Basic EPS | -$1.35 | -$0.51 | -$0.85 | -$0.53 |
| **Diluted EPS** | -$1.35 | -$0.51 | -$0.85 | -$0.53 |
| Basic Shares Outstanding | 23.7M | 15.4M | 13.9M | 13.2M |
| Diluted Shares Outstanding | -- | 15.4M | 13.9M | 13.2M |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $947K | $706K | $525K | $497K | $413K | $496K | $314K | $861K |
| Total Operating Expenses | $1.41M | $1.16M | $1.10M | $5.82M | $1.32M | $1.55M | $1.81M | $2.44M |
| Interest Expense | -- | -- | -- | -- | -- | -- | -$21K | -$38K |
| **Net Income** | -$1.42M | -$1.21M | -$1.15M | -$5.98M | -$1.14M | -$1.54M | -$1.78M | -$2.40M |
| Basic EPS | -- | -$0.03 | -$0.03 | -- | -$1.18 | -$0.09 | -$0.11 | -- |
| **Diluted EPS** | -$0.03 | -$0.03 | -$0.03 | -- | -$1.18 | -$0.09 | -$0.11 | -- |
| Basic Shares Outstanding | 42.0M | 42.0M | 41.9M | -- | 19.3M | 17.0M | 16.6M | -- |
| Diluted Shares Outstanding | -- | -- | -- | -- | 19.3M | 17.0M | 16.6M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $6.35M | $2.83M | $4.60M | $351K |
| Short-Term Investments | $4.68M | -- | -- | -- |
| **Cash & Short-Term Investments** | $11.03M | $2.83M | $4.60M | $351K |
| Accounts Receivable, Net | -- | $5.0K | $5.0K | -- |
| **Total Current Assets** | $11.06M | $2.89M | $4.86M | $494K |
| **Total Non-Current Assets** | $35K | $35K | $74K | $364K |
| **Total Assets** | $11.09M | $2.92M | $4.93M | $858K |
| Accounts Payable | $129K | $723K | $539K | $789K |
| Other Current Liabilities | $573K | -- | -- | -- |
| **Total Current Liabilities** | $702K | $723K | $558K | $1.37M |
| **Total Non-Current Liabilities** | $0 | $0 | $0 | $84K |
| **Total Liabilities** | $702K | $723K | $558K | $1.45M |
| **Total Debt (incl. Leases)** | -- | -- | $5.1K | $84K |
| Common Stock | $4.2K | $1.7K | $1.5K | $6.7K |
| Retained Earnings | -$39.58M | -$29.14M | -$21.29M | -$9.30M |
| **Total Stockholders' Equity** | $10.39M | $2.20M | $4.37M | -$596K |
| Total Equity | $10.39M | $2.20M | $4.37M | -$596K |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $2.50M | $3.61M | $4.82M | $6.35M | $2.64M | $730K | $1.21M | $2.83M |
| Short-Term Investments | $4.47M | $4.50M | $4.59M | $4.68M | $4.89M | -- | -- | -- |
| **Cash & Short-Term Investments** | $6.97M | $8.11M | $9.41M | $11.03M | $7.54M | $730K | $1.21M | $2.83M |
| Accounts Receivable, Net | -- | -- | -- | -- | -- | -- | -- | $5.0K |
| **Total Current Assets** | $7.23M | $8.17M | $9.43M | $11.06M | $7.60M | $833K | $1.36M | $2.89M |
| **Total Non-Current Assets** | $35K | $35K | $35K | $35K | $35K | $35K | $35K | $35K |
| **Total Assets** | $7.27M | $8.20M | $9.46M | $11.09M | $7.63M | $868K | $1.40M | $2.92M |
| Accounts Payable | $232K | $41K | $34K | $129K | $84K | $298K | $101K | $723K |
| Other Current Liabilities | -- | -- | -- | $573K | -- | -- | -- | -- |
| **Total Current Liabilities** | $426K | $41K | $115K | $702K | $84K | $298K | $106K | $723K |
| **Total Non-Current Liabilities** | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| **Total Liabilities** | $426K | $41K | $115K | $702K | $84K | $298K | $106K | $723K |
| Common Stock | $4.2K | $4.2K | $4.2K | $4.2K | $4.0K | $1.7K | $1.7K | $1.7K |
| Retained Earnings | -$43.36M | -$41.94M | -$40.73M | -$39.58M | -$33.60M | -$32.46M | -$30.92M | -$29.14M |
| **Total Stockholders' Equity** | $6.84M | $8.16M | $9.35M | $10.39M | $7.55M | $570K | $1.29M | $2.20M |
| Total Equity | $6.84M | $8.16M | $9.35M | $10.39M | $7.55M | $570K | $1.29M | $2.20M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Net Income | -$10.44M | -$7.85M | -$11.98M | -$7.06M |
| Stock-Based Compensation | $6.31M | $1.92M | $2.55M | $1.30M |
| Change in Receivables | -- | -- | -$12K | -- |
| **Operating Cash Flow** | -$4.66M | -$5.56M | -$4.53M | -$5.60M |
| Common Stock Issued | $7.01M | $3.61M | $7.70M | $2.90M |
| **Financing Cash Flow** | $8.18M | $3.79M | $8.78M | $3.15M |
| **Net Change in Cash** | $3.51M | -$1.77M | $4.25M | -$2.46M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$1.42M | -$1.21M | -$1.15M | -$5.98M | -$1.14M | -$1.54M | -$1.78M | -$2.40M |
| Stock-Based Compensation | $102K | $22K | $108K | $4.56M | $391K | $490K | $875K | $547K |
| **Operating Cash Flow** | -$1.30M | -$1.21M | -$1.20M | -$1.14M | -$1.10M | -$800K | -$1.63M | -$1.81M |
| Common Stock Issued | -- | -- | -- | $3.84M | $2.82M | $345K | $3.4K | -- |
| **Financing Cash Flow** | $194K | $0 | -$331K | $4.84M | $3.01M | $324K | $3.4K | $493K |
| **Net Change in Cash** | -$1.10M | -$1.21M | -$1.53M | $3.71M | $1.91M | -$476K | -$1.63M | -$1.31M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -100.5% | -357.0% | -273.9% | -- |
| Return on Assets (ROA) | -94.1% | -268.6% | -242.9% | -822.6% |
| Current Ratio | 15.75x | 3.99x | 8.70x | 0.36x |
| Quick Ratio | 15.71x | 3.92x | 8.26x | 0.26x |
| Debt to Equity | -- | -- | 0.00x | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -142.7% | -116.1% | -104.9% | -100.5% | -90.9% | -1362.6% | -611.9% | -357.0% |
| Return on Assets (ROA) | -134.4% | -115.6% | -103.6% | -94.1% | -89.9% | -894.3% | -565.5% | -268.6% |
| Current Ratio | 16.97x | 200.08x | 82.16x | 15.75x | 90.53x | 2.79x | 12.86x | 3.99x |
| Quick Ratio | 16.36x | 198.75x | 81.97x | 15.71x | 89.79x | 2.45x | 11.36x | 3.92x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
